Table 3.
Multivariate analysis for overall survival, progression-free survival, lymphoma-specific survival, and time to progression in the training set
| Variable | OS
|
PFS
|
LSS
|
TTP
|
||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Albumin ≥4 g/dL | 0.179 (0.065–0.445) | <0.0002 | 0.415 (0.218–0.774) | <0.006 | 0.205 (0.071–0.527) | <0.0008 | 0.362 (0.182–0.709) | <0.003 |
| ALC-DX ≥600 cells/μL | 0.516 (0.235–1.090) | 0.08 | 0.730 (0.400–1.335) | 0.3 | 0.471 (0.194–1.074) | 0.07 | 0.707 (0.380–1.329) | 0.3 |
| Hemoglobin <10.5 g/dL | 1.131 (0.456–2.959) | 0.8 | 1.229 (0.573–2.533) | 0.6 | na | na | ||
| IPS ≥3 | 1.286 (0.521–3.075) | 0.6 | 1.013 (0.512–2.066) | 0.9 | 1.068 (0.440–2.525) | 0.9 | 1.297 (0.659–2.651) | 0.5 |
| CR prior to APHSCT | 0.435 (0.068–1.555) | 0.2 | 0.618 (0.231–1.397) | 0.3 | 0.238 (0.013–1.209) | 0.09 | 0.600 (0.203–1.425) | 0.3 |
| A-LMR ≥1 | 0.102 (0.038–0.245) | <0.0001 | 0.162 (0.082–0.305) | <0.0001 | 0.050 (0.011–0.155) | <0.0001 | 0.106 (0.046–0.220) | <0.0001 |
Abbreviations: ALC-DX, absolute lymphocyte at diagnosis; A-LMR, autograft lymphocyte/monocyte ratio; APHSCT, autologous peripheral hematopoietic stem cell transplantation; CI, confidence interval; CR, complete response; HR, hazard ratio; IPS, International Prognostic Score; LSS, lymphoma-specific survival; na, not applicable; OS, overall survival; PFS, progression-free survival; TTP, time to progression.